AbClon Inc

Chart & performance

D1W1MN

P/E

—

P/S

84.84

EPS

—

Div yield, %

—

Shrs. gr., 5y

5.83%

Rev. gr., 5y

11.21%

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Founded in Seoul, South Korea, in 2010, AbClon Inc. is a biopharmaceutical company engaged in the discovery and development of antibody-based drugs, with operations spanning South Korea and Sweden. The firm's developmental pipeline encompasses therapies derived from distinct technological platforms: the NEST platform addresses breast and gastric cancers; the AffiMab platform targets colon cancer and various autoimmune conditions; and the CAR-T platform is engineered for hematologic and ovarian cancers.

URL

http://www.abclon.co.kr/

IPO date

Sep 18, 2017

Employees

Domiciled in

Incorporated in

Valuation

No data to show